emerging concepts in pancreatic cancer medicine: targeting the tumor stroma
Clicks: 14
ID: 198786
2013
Albrecht Neesse,1 Sebastian Krug,1 Thomas M Gress,1 David A Tuveson,2 Patrick Michl11Department of Gastroenterology, Endocrinology, Infectiology and Metabolism, Philipps University Marburg, Marburg, Germany; 2Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USAAbstract: Pancreatic ductal adenocarcinoma is a stroma-rich and highly challenging cancer to treat. Over recent years, it has become increasingly evident that the complex network of soluble cytokines, growth factors, proteases, and components of the extracellular matrix collaboratively interact within the tumor microenvironment, sustaining and driving cancer cell proliferation, invasion, and early metastasis. More recently, the tumor microenvironment has also been appreciated to mediate therapeutic resistance in pancreatic ductal adenocarcinoma, thus opening numerous avenues for novel therapeutic explorations. Inert and soluble components of the tumor stroma have been targeted in order to break down the extracellular matrix scaffold, relieve vessel compression, and increase drug delivery to hypovascular tumors. Moreover, targeting of antiapoptotic, immunosuppressive, and pro-proliferative effects of the tumor stroma provides novel vantage points of attack. This review focuses on current and future developments in pancreatic cancer medicine, with a particular emphasis on biophysical and biochemical approaches that target the tumor microenvironment.Keywords: pancreatic cancer, chemoresistance, tumor stroma, drug delivery
Reference Key |
a2013oncotargetsemerging
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
---|---|
Authors | ;Neesse A;Krug S;Gress TM;Tuveson DA;Michl P |
Journal | jurnal tam |
Year | 2013 |
DOI | DOI not found |
URL | |
Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.